Shareholders to Vote on Highly Dilutive Warrant Issuances Amidst Financial Distress
Summary
Tempest Therapeutics is asking shareholders to approve the issuance of warrants that could dilute existing shares by nearly 30%, a critical step for the financially distressed company to secure needed capital and comply with Nasdaq rules.
Key Events
-
Shareholder Vote on Warrant Issuances
A Special Meeting of Stockholders is scheduled for June 18, 2026, to vote on two proposals related to the issuance of common stock upon the exercise of outstanding warrants.
-
Approval for PIPE Warrants
Shareholders will vote on the issuance of up to 1,851,854 shares from Series A and Series B Warrants, issued in connection with a March 2026 private placement, with an exercise price of $2.16 per share. This represents approximately 12.91% potential dilution.
-
Approval for Inducement Warrants
Shareholders will also vote on the issuance of up to 2,344,828 shares from Inducement Warrants (plus 82,069 PA Warrants), issued as part of a May 2026 inducement offer. This offer involved reducing the exercise price of existing warrants from $3.50 to $1.73 and issuing new warrants at $1.73 per share, representing approximately 16.92% potential dilution.
-
Significant Potential Dilution
If both proposals are approved and all warrants are exercised, it could result in the issuance of 4,278,751 new shares, representing approximately 29.83% dilution to current outstanding shares.
Analysis
Tempest Therapeutics is seeking shareholder approval for two proposals that, if passed, would allow for the issuance of warrants representing approximately 30% of its outstanding shares. This comes as the company faces a 'going concern' warning and Nasdaq deficiency notices, highlighting a critical need for capital. The second proposal, an inducement offer, is particularly concerning as it involves reducing the exercise price of existing warrants and issuing new, additional warrants, indicating the company's struggle to secure financing on favorable terms. While these measures are crucial for liquidity and operational runway, they come at a significant cost to existing shareholders through substantial dilution.
At the time of this filing, TPST was trading at $1.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.7M. The 52-week trading range was $1.50 to $12.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.